Evidence mapPaperPMID 42356391Full record

ReviewNutrients2026

Ketogenic Diet in Obesity and Diabetes: A Narrative Review.

Yousun An, Nicholas Norris, Donglai Li, Jenny E Gunton

Abstract readReview
In one paragraph

Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yousun AnCentre for Diabetes, Obesity and Endocrinology, Westmead Institute for Medical Research, University of Sydney, Westmead, NSW 2145, Australia.ORCID 0009-0006-1302-8346
Nicholas NorrisCentre for Diabetes, Obesity and Endocrinology, Westmead Institute for Medical Research, University of Sydney, Westmead, NSW 2145, Australia.ORCID 0000-0003-2118-9706
Donglai LiCentre for Diabetes, Obesity and Endocrinology, Westmead Institute for Medical Research, University of Sydney, Westmead, NSW 2145, Australia.ORCID 0000-0002-8610-5000
Jenny E GuntonCentre for Diabetes, Obesity and Endocrinology, Westmead Institute for Medical Research, University of Sydney, Westmead, NSW 2145, Australia.ORCID 0000-0002-8127-9773

Funding

National Health and Medical Research Council 2033228The University of Sydney Metabolic Health InitiativeThe University of Sydney Musculoskeletal Health Program
6 · The paper itself

Abstract

A ketogenic diet (KD) is a low-carbohydrate, high-fat dietary approach. Beyond treating neurologic disorders, KDs have attracted significant media attention for their potential to improve obesity and diabetes. The diet induces a metabolic shift from glucose toward fatty acid oxidation and ketone body production. This shift leads to ketosis, which may reduce hunger, partly through the anorexigenic effects of ketone bodies, thereby contributing to weight loss and improved metabolic parameters, including glycaemic control and insulin sensitivity. In particular, the positive effects of KDs lower insulin demand and may thereby improve β-cell function. However, the long-term efficacy, safety, and sustainability of KDs, especially for diabetes, remain debated. This review offers current insights into the effects of ketogenesis and ketosis, as well as the potential mechanisms underlying them. We explore the metabolic effects of KDs in obesity and diabetes, drawing on preclinical and clinical studies, and suggest that combining KDs with antidiabetic agents may provide synergistic benefits. However, combining KDs with these pharmacotherapies, particularly SGLT-2 inhibitors, requires careful clinical supervision because of potential risks, including euglycaemic diabetic ketoacidosis. We explore how a KD alters the composition of the gut microbiota, thereby affecting host health. We conclude by highlighting challenges and future directions for optimising KD-based therapies and by outlining the limitations of the current review.

Indexed as

Diabetes MellitusDiabetes Mellitus, Type 2Diet, KetogenicObesityAnimalsHumansHypoglycemic AgentsKetone BodiesWeight LossHypoglycemic AgentsKetone Bodiesdiabetesglycaemic controlgut healthimmune responseKDobesityweight lossβ-cells

Identifiers

PMID42356391
PMCPMC13304935

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.